ACTRN12611000824965
Withdrawn
Phase 4
Comparison of immunogenicity of Monovalent oral polio vaccine (mOPVI) administered at short intervals with Monovalent (mOPVI) and Bivalent (bOPV1,3) oral polio vaccine given at standard intervals in healthy infants in Pakistan: a randomized trial
Department of Paediatrics and Child Health, Aga Khan University0 sites800 target enrollmentAugust 4, 2011
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Poliomyelitis
- Sponsor
- Department of Paediatrics and Child Health, Aga Khan University
- Enrollment
- 800
- Status
- Withdrawn
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infants born healthy (\> 2\.5 kg birth weight, immediate cry, no neonatal IMCI danger signs) at the study sites (home or health facility births assisted by study\-Trained Birth Attendants/other health personnel) and not planning to travel away during entire the study period (birth\-102 days).
Exclusion Criteria
- •High\-risk newborns will be excluded, as well as newborns requiring hospitalization, birth weight below 2\.5 kg, cry \>2 minutes, and with any neonatal IMNCI danger signs, residence \>30 km from study site, or family is planning to be absent during the birth \- 102 day study period. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family \- e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study. Subjects will be re\-screened for eligibility at the 6 week visit before randomization to study arms. Infants with illness requiring hospitalization, weight \<2\.5 kg, family planning to be away during the next 10 weeks, or unwilling to have another blood draw will be excluded from randomization. The families of babies with exclusion criteria will be informed about immediate treatment options if their baby is sick (hospital referral and in case of refusal centre\-based outpatient care), need for receipt of routine immunizations, and reassured about long term continued assessment and primary level care at the PHC.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Comparative evaluation of immunogenicity of Monovalent Type 1 Oral Poliovirus Vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in India (Panacea Biotec Ltd mOPV1 study)PolioInfections and InfestationsISRCTN80143849Panacea Biotec Ltd (India)600
Completed
Not Applicable
Comparative evaluation of Immunogenicity of monovalent type 1 Oral Poliovirus Vaccine (mOPV1) and monovalent type 3 Oral Poliovirus Vaccine (mOPV3) versus trivalent Oral Poliovirus Vaccine (tOPV): a randomised double-blind controlled trial in South AfricaPoliomyelitisInfections and InfestationsISRCTN18107202World Health Organization (WHO) (Switzerland)800
Completed
Not Applicable
Comparative evaluation of immunogenicity of monovalent type 1 oral poliovirus vaccine (mOPV1) versus trivalent OPV (tOPV): a randomised double-blind trial set in EgyptPolioInfections and InfestationsISRCTN76316509World Health Organization (WHO) (Switzerland)600
Completed
Phase 2
clinical trial of the effect of raw and cooked milk immunotherapy in children with milk allergyIRCT20170426033658N2Vice chancellor for Research of Tehran University of Medical Sciences25
Recruiting
Phase 4
Comparing immune response to oral polio vaccine administered at short intervals with vaccine administered at standard intervals in healthy newborns in PakistapoliomyelitisInfection - Other infectious diseasesPublic Health - Other public healthACTRN12612000276853WHO800